Oral small molecule GLP-1 receptor agonist
Orforglipron 6 mg oral once daily
ORFO_PO_6MG_QD
Related
- All doses pooled: Orforglipron tablet
- Orforglipron 12 mg oral once daily
- Orforglipron 36 mg oral once daily
- Orforglipron 3 mg oral once daily
- Orforglipron maximum tolerated dose tablet once daily
- Orforglipron 1 mg tablet once daily
- Orforglipron 14.5 mg tablet once daily
- Orforglipron 17.2 mg tablet once daily
- Orforglipron 0.8 mg tablet once daily
- Orforglipron 2.5 mg tablet once daily
- Orforglipron 5.5 mg tablet once daily
- Orforglipron 9 mg tablet once daily
- Orforglipron 24 mg oral once daily
- Orforglipron 45 mg oral once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.83 (0.48 to 1.35) | 0.59 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.65 (1.60 to 4.31) | 0.51 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.67 (2.05 to 6.45) | 0.40 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.65 (1.11 to 2.42) | 0.49 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.59 (1.63 to 4.16) | 0.31 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -6.70 (-13.11 to 2.58) | 0.17 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.18 (0.58 to 2.47) | 0.49 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.15 (2.24 to 4.54) | 0.58 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.51 (1.96 to 6.08) | 0.59 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.21 (1.25 to 3.58) | 0.44 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.50 (1.26 to 4.87) | 0.42 |
Trials
- ATTAIN-2A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)2023 · 1,613 randomized · 72 weeks
- ATTAIN-1A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)2023 · 3,127 randomized · 72 weeks